Last C$23.20 CAD
Change Today +0.49 / 2.16%
Volume 332.0K
TKM On Other Exchanges
Symbol
Exchange
Berlin
Toronto
NASDAQ CM
As of 4:25 PM 08/29/14 All times are local (Market data is delayed by at least 15 minutes).

tekmira pharmaceuticals corp (TKM) Snapshot

Open
C$21.96
Previous Close
C$22.71
Day High
C$23.57
Day Low
C$21.43
52 Week High
03/11/14 - C$34.66
52 Week Low
08/30/13 - C$5.47
Market Cap
512.9M
Average Volume 10 Days
402.2K
EPS TTM
C$-1.72
Shares Outstanding
22.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for TEKMIRA PHARMACEUTICALS CORP (TKM)

tekmira pharmaceuticals corp (TKM) Related Businessweek News

No Related Businessweek News Found

tekmira pharmaceuticals corp (TKM) Details

Tekmira Pharmaceuticals Corporation, a biopharmaceutical company, focuses on the research and development of RNA interference therapeutics; and provides lipid nanoparticle delivery technology to pharmaceutical partners in Canada. Its pipeline products include TKM-PLK1, an oncology product platform that is in Phase I/II clinical trials, which targets polo-like kinase 1, a protein involved in tumor cell proliferation and a validated oncology target; and TKM-HBV, which is in Phase I clinical trial to eliminate surface antigen expression in the chronically infected patients. The company is also involved in developing TKM-Ebola, an anti-ebola viral therapeutic that is in Phase I clinical trial; and TKM-Marburg to treat Marburg infections. In addition, its preclinical product candidate includes TKM-ALDH2 for the treatment of alcohol use disorder. The company has strategic alliances with Alnylam Pharmaceuticals, Inc.; Acuitas Therapeutics Inc.; Spectrum Pharmaceuticals, Inc.; Monsanto Company; Marina Biotech, Inc./Arcturus Therapeutics, Inc.; Merck & Co., Inc.; Bristol-Myers Squibb Company; and U.S. National Institutes of Health. Tekmira Pharmaceuticals Corporation is headquartered in Burnaby, Canada.

tekmira pharmaceuticals corp (TKM) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $377.5K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $69.5K
Chief Technical Officer and Executive Vice Pr...
Total Annual Compensation: $305.9K
Senior Vice President of Pharmaceutical Devel...
Total Annual Compensation: $233.0K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $128.6K
Compensation as of Fiscal Year 2013.

tekmira pharmaceuticals corp (TKM) Key Developments

GlaxoSmithKline and Shire Looking To Acquire Tekmira Pharmaceuticals

GlaxoSmithKline plc (LSE: GSK) and Shire plc (LSE:SHP) are rumoured to be eyeing Tekmira Pharmaceuticals Corporation (TSX: TKM) according to Daily Mail. Tekmira Pharmaceuticals is developing an experimental treatment for the deadly ebola virus which has already claimed lives of more than 1,000 people in Africa.

Tekmira Pharmaceuticals Corporation Announces Resignation of Kenneth Galbraith as Member of Board of Directors

On August 22, 2014, Kenneth Galbraith delivered to Tekmira Pharmaceuticals Corporation notice of his resignation as a member of the Board of Directors of Tekmira Pharmaceuticals Corporation, effective immediately upon delivery. To the knowledge of the Corporation, Mr. Galbraith's resignation was not the result of any disagreement with the Corporation relating to the Corporation's operations, policies or practices. Mr. Galbraith had served as a member of the Board of Directors since January 2010.

Tekmira Pharmaceuticals Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

Tekmira Pharmaceuticals Corporation reported earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company's net loss was $6.1 million or $0.28 per common share as compared to $3.0 million or $0.21 per common share a year ago. This increased loss largely reflects expense increases of $5.3 million offset by other income gains of $3.1 million, relating to foreign exchange and warrant revaluation. Revenue was $1.8 million as compared to $2.8 million a year ago. For the first half, the company's net loss was $24.1 million or $1.15 per common share as compared to $5.6 million or $0.39 per common share a year ago. This increased loss largely reflects expense increases of $10.6 million and other income losses of $9.3 million relating to foreign exchange losses and warrant revaluation.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TKM:CN C$23.20 CAD +0.49

TKM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Benitec Biopharma Ltd A$0.98 AUD -0.055
Galena Biopharma Inc $2.36 USD -0.03
Prosensa Holding NV $9.10 USD -0.05
Regulus Therapeutics Inc $6.88 USD +0.08
Silence Therapeutics PLC 210.00 GBp -4.87
View Industry Companies
 

Industry Analysis

TKM

Industry Average

Valuation TKM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 27.6x
Price/Book 4.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 20.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TEKMIRA PHARMACEUTICALS CORP, please visit www.tekmirapharm.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.